Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Heart Failure and Transthyretin or Light Chain Amyloidosis: A Real-World Analysis
Arquivos Brasileiros de Cardiologia · 2026-01 · 123 (1)
DOI: 10.36660/abc.20250439i ↗Kurz gefasst
Fachartikel in der Zeitschrift Arquivos Brasileiros de Cardiologia, 2026-01. Verfasst von Rafael Amorim Belo Nunes und 5 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Evidence regarding the efficacy of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in amyloidosis-related heart failure (HF) remains limited.
Objective
To evaluate the impact of SGLT2i in patients with amyloid transthyretin (ATTR) or amyloid light-chain (AL) amyloidosis and HF.
Methods
By using global electronic medical record data, we identified patients aged ≥ 18 years with ATTR or AL amyloidosis and HF. After matching, outcomes were compared between patients treated with SGLT2i and matched controls, including 2,036 patients with ATTR amyloidosis and 692 patients with AL amyloidosis. Endpoints included 12-month all-cause mortality, hospitalization, and kidney outcomes. Statistical significance was defined as a two-sided p < 0.05.
Results
A total of 96 (9.43%) deaths occurred among patients with ATTR amyloidosis in the SGLT2i group, compared to 196 (19.2%) in the control group (hazard ratio [HR], 0.52; 95% CI, 0.41-0.66). Hospitalization occurred in 387 (38.0%) patients receiving SGLT2i and in 505 (49.6%) controls (HR, 0.74; 95% CI, 0.65-0.84). Kidney outcomes were observed in 204 (20.0%) patients in the SGLT2i group and 298 (28.5%) in the control group (HR, 0.72; 95% CI, 0.60-0.86). Among patients with AL amyloidosis, 39 (11.2%) deaths occurred in the SGLT2i group and 80 (23.1%) in the control group (HR, 0.51; 95% CI, 0.34-0.74). Hospitalization occurred in 161 (46.5%) patients treated with SGLT2i and in 204 (58.96%) controls (HR, 0.71; 95% CI, 0.58-0.88). Kidney outcomes occurred in 86 (24.8%) patients in the SGLT2i group and 137 (39.6%) in the control group (HR, 0.60; 95% CI, 0.46-0.78).
Conclusion
In patients with HF due to ATTR or AL amyloidosis, the use of SGLT2i was associated with lower all-cause mortality, hospitalization, and kidney outcomes.
Zitieren
APA
Nunes, R. A. B., Costa, L. M. A. D., Scudeler, T. L., Neves, P. D. M. M., Sato, V. A. H., & Avezum, Á. (2026). Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Heart Failure and Transthyretin or Light Chain Amyloidosis: A Real-World Analysis. Arquivos Brasileiros de Cardiologia, 123(1). https://doi.org/10.36660/abc.20250439i
Vancouver
Nunes RAB, Costa LMAD, Scudeler TL, Neves PDMM, Sato VAH, Avezum Á. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Heart Failure and Transthyretin or Light Chain Amyloidosis: A Real-World Analysis. Arquivos Brasileiros de Cardiologia. 2026;123(1). doi:10.36660/abc.20250439i
BibTeX
@article{Nunes2026,
author = {Nunes, Rafael Amorim Belo and Costa, Leandro Menezes Alves da and Scudeler, Thiago Luis and Neves, Precil Diego Miranda Menezes and Sato, Victor Augusto Hamamoto and Avezum, Álvaro},
title = {Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Heart Failure and Transthyretin or Light Chain Amyloidosis: A Real-World Analysis},
journal = {Arquivos Brasileiros de Cardiologia},
year = {2026},
volume = {123},
number = {1},
doi = {10.36660/abc.20250439i}
}
EUVIMED